Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06627647 · ClinicalTrials.gov registry record · Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
A Phase 3 study of Non-squamous Non-small Cell Lung Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 878
- Enrollment target
- 20
- Study locations
NCT06627647 is a Phase 3 study of Non-squamous Non-small Cell Lung Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 878 participants, above the 278-participant average among 7 other Non-squamous Non-small Cell Lung Cancer trials with a reported enrollment target (216% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT06627647, a Phase 3 study of Non-squamous Non-small Cell Lung Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 878 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Rilvegostomig
Study Locations (20)
California
- Research Site - Anaheim
- Research Site - Beverly Hills
- Research Site - Loma Linda
- Research Site - Redlands
- Research Site - San Diego
- Research Site - San Francisco
- Research Site - Santa Rosa
- Research Site - Walnut Creek
Florida
- Research Site - Bay Pines
- Research Site - Fort Lauderdale
- Research Site - Gainesville
- Research Site - Jacksonville
- Research Site - Miami
Arizona
- Research Site - Chandler
- Research Site - Phoenix
Connecticut
- Research Site - Stamford
- Research Site - West Haven
Alabama
- Research Site - Mobile
Colorado
- Research Site - Lone Tree
Delaware
- Research Site - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 878 participants |
| Start Date | 2024-11-27 |
| Est. Completion | 2030-03-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06627647
The ClinicalTrials.gov registry entry for NCT06627647 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 878 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 278-participant average among 7 other Non-squamous Non-small Cell Lung Cancer trials with a reported enrollment target (216% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-squamous Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06627647 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06627647 about?
NCT06627647 is a clinical study titled "A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC". The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.
What is the current status of trial NCT06627647?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 878 participants. The study started on 2024-11-27. Estimated completion is 2030-03-25.
What conditions does trial NCT06627647 study?
This clinical trial studies the following conditions: Non-squamous Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT06627647?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Rilvegostomig (DRUG).
Who is sponsoring clinical trial NCT06627647?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06627647 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-squamous Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase III Study of AK112 for NSCLC Patients
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
COMPLETED · Phase 3
-
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
COMPLETED · Phase 3
-
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.